Kura Oncology’s Menin-MLL Inhibitor KO-539 Receives Orphan Drug Designation from FDA for Treatment of Acute Myeloid Leukemia

NEXT STORY
Synthorx Initiates Patient Dosing in Australia and Announces Clearance of IND in the U.S. for Lead Immuno-oncology Product Candidate, THOR-707
PREV STORY
EyePoint Pharmaceuticals Announces Second Quarter 2019 Financial Results Release Date and Conference Call Information
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Lung Cancer Care and Research Not Immune to Socioeconomic, Ethnic, Racial, and Gender-related Factors that Create Disparities

author_avatar
NASDAQ Market News

Summit Therapeutics plc : 1st Quarter Results

Summit Therapeutics plc('Summit', the 'Company' or the 'Group') SUMMIT THERAPEUTICS REPORTS FINANCIAL RESULTS FOR ...

author_avatar
NASDAQ Market News

Telehealth Ventilators Worth More Than RM2 Million to be Donated to Malaysian Hospitals to Treat COVID-19 Patients in Intensive Care

author_avatar
NASDAQ Market News